Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation

Clinical Transplantation

Volumn 22, Issue 1, 2008, Pages 98-106

  Aguero, Jaime ^a   Almenar, Luis ^a   Martínez Dolz, Luis ^a   Moro, Jose A ^a   Rueda, Joaquin ^a   Raso, Rafael ^a   Chamorro, Carlos ^a   Sanchez, Juan M ^a   Salvador, Antonio ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Complications; Heart transplantation; Immunosuppression; Infection; Rejection; Survival

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; DEFLAZACORT; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INSULIN; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OKT 3; STEROID;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DYSLIPIDEMIA; ESOPHAGUS CANDIDIASIS; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THRUSH; TUBERCULOSIS;

ADULT; CAUSE OF DEATH; COMORBIDITY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 38549178944     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00751.x     Document Type: Article

References (30)

1. Lindenfeld J, Miller GG, Shakar S et al. Drug therapy in the heart transplant recipient part I: Cardiac rejection and immunosuppressive drugs. Circulation 2004: 110: 3734.
2. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006: 6: 1111.
3. Aguero J, Almenar L, Martínez-Dolz L et al. Influence of immunosuppression regimen on heart transplantation survival. Transplant Proc 2006: 38: 2550.
4. Marelli D, Laks H, Patel B et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003: 22: 1091.
5. Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006: 25: 869.
6. Almenar L. Spanish Heart Transplantation Registry. 16th official report of the Spanish Society of Cardiology Working Group on Heart Failure, Heart Transplantation, and Associated Therapies. Rev Esp Cardiol 2005: 58: 1310.
7. Real Decreto 2070/1999, for the regulation of human organs obtaining and clinical use activities, and territory coordination for organ and tissue donation and transplantation. B O E 2000: 3: 179.
8. Del Rizzo DF, Menkis AH, Pflugfelder PW et al. The role of donor age and ischemic time on survival following orthotopic heart transplantation. J Heart Lung Transplant 1999: 18: 310.
9. Morgan JA, John R, Weinberg AD et al. Prolonged donor ischemic time does not adversely affect long-term survival in adult patients undergoing cardiac transplantation. J Thorac Cardiovasc Surg 2003: 126: 1624.
10. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006: 81: 1542.
11. van Gelder T, Balk AH, Jonkman FA et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996: 62: 51.
12. Bonaros N, Dunkler D, Kocher A et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant 2006: 25: 1154.
13. Kobashigawa J, David K, Morris J et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005: 37: 1333.
14. Hershberger RE, Starling RC, Eisen HJ et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005: 352: 2705.
15. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998: 66: 507.
16. Eisen HJ, Kobashigawa J, Keogh A et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005: 24: 517.
17. Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 2001: 72: 1662.
18. Beniaminovitz A, Itescu S, Lietz K et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000: 342: 613.
19. Mehra MR, Zucker MJ, Wagoner L et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005: 24: 1297.
20. Chin C, Pittson S, Luikart H et al. Induction therapy for pediatric and adult heart transplantation: Comparison between OKT3 and daclizumab. Transplantation 2005: 80: 477.
21. Miller LW, Naftel DC, Bourge RC et al. Infection after heart transplantation: A multiinstitutional study Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994: 13: 381.
22. Smart FW, Naftel DC, Costanzo MR et al. Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study. J Heart Lung Transplant 1996: 15: 329.
23. Hertz MI, Taylor DO, Trulock EP et al. The registry of the International Society for Heart and Lung Transplantation: Nineteenth official report - 2002. J Heart Lung Transplant 2002: 21: 950.
24. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant 2004: 5 (Suppl): S194.
25. Kobashigawa JA, Starling RC, Mehra MR et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006: 25: 1063.
26. Valantine H, Rickenbacker P, Kemna M et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease. Circulation 2001: 103: 2144.
27. Garrido IP, Crespo-Leiro MG, Paniagua MJ et al. Independent predictors of renal dysfunction after heart transplantation in patients with normal pretransplant renal function. J Heart Lung Transplant 2005: 24: 1226.
28. Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 2002: 73: 1169.
29. Grimm M, Rinaldi M, Yonan NA et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006: 6: 1387.
30. John R, Rajasinghe HA, Chen JM et al. Long-term outcomes after cardiac transplantation: An experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001: 72: 440.